Capital Flow Monitor · Sponsors · CIK 2086124
Merge Bio Therapeutics Corp
1 KENDALL SQUARE, BUILDING 200, CAMBRIDGE, MA, 02139 · 617-286-2631
Other · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$15.0M
Sold
$5.0M
% sold
33.3%
Investors
1
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-09-17 | D ·current | 506(b) | $15.0M | $5.0M | 33.3% | 1 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Steve Liapis — Director, Cambridge, MA
- Elias Quijano — Director, Cambridge, MA
-
Wesley Wong — Executive Officer / Director / Promoter, Cambridge, MA
3 other raises
- Oxbow Master Fund Ltd $1.27B of —
- Oxbow Fund (Onshore) Ltd $937.5M of —
- Oxbow Fund (Offshore) Ltd $42.2M of —
- Clinton Hansen — Executive Officer / Promoter, Cambridge, MA
- Mark Lipstein — Promoter, Cambridge, MA
- Darren Yang — Promoter, Cambridge, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.